High cancer drug prices significantly contribute to health care costs in the United States, with the average annual price of new cancer drugs increasing from less than $10,000 before 2000 to $145,000 in 2015. Baker Institute fellows Hagop M. Kantarjian and Vivian Ho highlight this issue and propose possible solutions.
This policy brief is part of a series of recommendations from the Baker Institute for the incoming president’s administration.
Jan. 20, 2017, 5:55 p.m.
Kevin Erickson, M.D., is a nonresident scholar in the Center for Health and Biosciences. He is an assistant professor in the Section of Nephrology and an investigator at the Center for Innovations in Quality, Effectiveness and Safety at Baylor College …
Peter J. Hotez, M.D., Ph.D., is the Baker Institute fellow in disease and poverty. He is dean of the National School of Tropical Medicine and professor of pediatrics and molecular virology and microbiology at Baylor College of …
